Nodthera Limited

Alan Paul Watt

David Harrison

Mark G Bock

Oleksandr Levenets

Michal Galezowski

Charles-Henry Fabritius

Grzegorz Witold Topolnicki

Roderick Alan Porter

Charles-Henry Robert Yves Fabritius

Nicolas Boutard

Piotr Kowalczyk

Jakub Woyciechowski

Nicolas Felix Pierre Boutard

The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.

Sulphonyl urea derivatives as NLRP3 inflammasome modulators

The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as autoinflammatory and autoimmune diseases and cancers.

Selective inhibitors of NLRP3 inflammasome

The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein inhibit the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inter alia autoinflammatory and autoimmune diseases and cancers. 

Urea derivatives and methods of use thereof

Growing community of inventors

Essex, United Kingdom

Alan Paul Watt